
Branimir Ivan Sikic, M.D.

Professor of Medicine, Stanford University



Branimir I. Sikic, M. D., is Professor of Medicine in the Division of Oncology at Stanford University School of Medicine. He has directed the General Clinical Research Center of Stanford University and then the Center for Clinical and Translational Research for the past 24 years. He has authored more than 240 publications, with more than 13,300 citations and an h-index of 65. He has also edited two books, and is the inventor of two U.S. patents. He has served on several advisory committees of the National Institutes of Health, chaired the Scientific Program Committee for the American Society of Clinical Oncology (ASCO) in 2005-6, and in 2008-9 was co-chair of the Program Committee of the American Association for Cancer Research (AACR). In 2010 he was awarded the Katarina Zrinska medal for science and medicine by the government of Croatia. Dr. Sikic is a leader in the pharmacology of anticancer drugs and the development of new cancer therapies, and has made major contributions to understanding the problem of multidrug resistance in cancers. His current laboratory research includes studies of the role of microtubules and tubulin dynamicity in cancer resistance to taxane drugs, and the preclinical efficacy of a new immunotherapy with the antibody Hu5F9-G4, that inhibits the CD47-SIRPα macrophage checkpoint. He is also conducting the first-in-human, first-in-class Phase I trial of this anti-CD47 antibody.